BMY - Bristol-Myers Squibb Company (BMY) Q4 2023 Earnings Call Transcript

2024-02-02 12:43:08 ET

Bristol-Myer Squibb Company (BMY)

Q4 2023 Earnings Conference Call

February 2, 2024 08:00 AM ET

Company Participants

Tim Power - VP, IR

Chris Boerner - CEO

David Elkins - EVP & CFO

Sarnit Hirawat - Chief Medical Officer

Adam Lenkowsky - Chief Commercialization Officer

Conference Call Participants

Luisa Hector - Berenberg

Chris Schott - JP Morgan

Andrew Baum - Citi

Seamus Fernandez - Guggenheim

Tim Anderson - Wolfe Research

Trung Huynh - UBS

Geoff Meacham - Bank of America

Matt Phipps - William Blair

Steve Scala - TD Cowen

Terence Flynn - Morgan Stanley

Evan Siegerman - BMO Capital Markets

Carter Gould - Barclays

Robyn Karnauskas - Truist

James Sheehan - Deutsche Bank

Akash Tiwari - Jefferies

Rajesh Kumar - HSBC

Presentation

Operator

Welcome to the Bristol-Myers Squibb Fourth Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Tim Power, Vice President and Head of Investor Relations. Please go ahead.

Tim Power

Thank you, and good morning, everyone. Thanks for joining us this morning for our fourth quarter 2023 earnings call. Joining me this morning with prepared remarks are Chris Boerner, our Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer; and Samit Hirawat, our Chief Medical Officer and Head of Global Drug Development. As you'll note, we've posted slides to bms.com that you can use to follow along with for Chris and David's remarks.

Before we get started, I'll read our forward-looking statement. During this call, we'll make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change.

We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com.

And with that, I'll hand it over to Chris.

Chris Boerner

Thanks, Tim, and good morning to all of you. I'm very pleased to be speaking to you on our earnings call for the first-time as a CEO, and I'm excited about the opportunity for our company to continue to deliver transformational medicines for patients....

For further details see: